Vnitr Lek 2018, 64(4):343-346 | DOI: 10.36290/vnl.2018.051

Epicardial fat and osteoprotegerin - does a mutual relation exist? Pilot study

Markéta Sovová1,*, Eliška Sovová2, Jana Zapletalová3, Markéta Kaletová2, David Stejskal4, Milan Sova5, Michal Konečný1, Vlastimil Procházka1, Drahomíra Vrzalová1, Lea Zarivnijová1
1 II. interní klinika - gastroenterologická a hepatologická LF UP a FN Olomouc
2 Klinika tělovýchovného lékařství a kardiovaskulární rehabilitace LF UP a FN Olomouc
3 Ústav lékařské biofyziky LF UP Olomouc
4 Ústav lékařské chemie a biochemie LF UP Olomouc
5 Klinika plicních nemocí a tuberkulózy LF UP a FN Olomouc

Introduction:
Epicardial fat (EPI) plays important role in development of metabolic and cardiovascular diseases. According to population studies EPI represents independent risk factor of cardiovascular diseases (CVD) and also for neoplasms. Osteoprotegerin (OPG) is a glycoprotein which have role in regulation of immune and cardiovascular systems. High serum levels of OPG are connected with high cardiovascular risk.


The aim of our study was to evaluate possible correlation between EPI and OPG level in asymptomatic relatives of patients with CVD.

Material and methods:
53 asymptomatic relatives (37 male) (median age 53 years) of patients with CVD (ischemic heart disease, cerebrovascular disease) were included. Physical examination and biochemistry analysis were performed. GE Vivid 7 (GE Medical) was used for echocardiography. EPI was measured according to guidelines using parasternal long axis in diastole as a space in front of right ventricle.

Results:
EPI was present in 46 subjects (86.8 %) with mean value of 2.91 mm. In 10 subjects was the amount of EPI > 5 mm. Spearmann correlation analysis found statistically significant correlation between EPI and OPG (r = 0.271; p = 0.05) and age (r = 0.500; p < 0.0001). We have not found correlation between EPI, glycaemia and level of insulin, glycated Hb, total, LDL, HDL cholesterol and triglycerides.

Conclusion:
We have found positive correlation between EPI and OPG. More studies are needed to confirm applicability of this correlation in risk stratification.

Keywords: cardiovascular risk; epicardial fat; osteoprotegerin

Received: March 29, 2017; Accepted: January 1, 2018; Published: April 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sovová M, Sovová E, Zapletalová J, Kaletová M, Stejskal D, Sova M, et al.. Epicardial fat and osteoprotegerin - does a mutual relation exist? Pilot study. Vnitr Lek. 2018;64(4):343-346. doi: 10.36290/vnl.2018.051.
Download citation

References

  1. Piepoli MF, Hoes AW, Agewall S et al. [European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice]. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Dostupné z DOI: <http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelines-CVD-prevention.pdf>.
  2. Shimabukuro M, Kozuka C, Taira S et al. Ectopic fat deposition and global cardiometabolic risk: new paradigm in cardiovascular medicine. J Med Invest 2013; 60(1-2): 1-14. Go to original source... Go to PubMed...
  3. Bertaso AG, Bertol D, Duncan BB et al. Epicardial fat: definition, measurements and systematic review of main outcomes. Arq Bras Cardiol 2013; 101(1): e18-e28. Dostupné z DOI: <http://dx.doi.org/10.5935/abc.20130138>. Go to original source... Go to PubMed...
  4. Cherian S, Lopaschuk GD, Carvalho E. Cellular cross-talk between epicardial adipose tissue and myocardium in relation to the pathogenesis of cardiovascular disease. Am J Physiol Endocrinol Metab 2012; 303(8): 937-949. Dostupné z DOI: <http://dx.doi.org/10.1152/ajpendo.00061.2012>. Go to original source... Go to PubMed...
  5. Rosito GA, Massaro JM, Hoffmann U et al. Pericardial fat,visceral abdominal fat, cardiovascular disease risk factors and vascular calcification in a community based sample: the Framingham Heart Study. Circulation 2008; 117(5): 605-613. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.107.743062>. Go to original source... Go to PubMed...
  6. Ding J, Hsu FC, Harris TB et al. The association of pericardial fat with incident coronary heart disease. The Multiethnic Study of Atherosclerosis (MESA). Am J Clin Nutr 2009; 90(3): 499-504. Dostupné z DOI: <http://dx.doi.org/10.3945/ajcn.2008.27358>. Go to original source... Go to PubMed...
  7. Britton KA, Massaro JM, Murabito JM et al. Body fat distribution, incident cardiovascular disease, cancer, and all cause mortality. J Am Coll Cardiol 2013; 62(10): 921-925. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2013.06.027>. Go to original source... Go to PubMed...
  8. Oikawa M, Owada T, Yamauchi H et al. Epicardial adipose tissue reflects the presence if coronary artery disease: comparison with abdominal visceral adipose tissue. Biomed Res Int 2015; 2015: 483982. Dostupné z DOI: <http://dx.doi.org/10.1155/2015/483982>. Go to original source... Go to PubMed...
  9. Schoppet M, Preissner KT, Hofbauer LC. Rank ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Atherioscler Thromb Vasc Biol 2002; 22(4): 549-553. Go to original source... Go to PubMed...
  10. Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89(2): 309-319. Go to original source... Go to PubMed...
  11. Hofbauer LC, Shui C, Riggs BL et al. Effects of immunosuppressants on receptor activator of NF-kappa B ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cels. Biochem Biophys Res Commun 2001; 280(1): 334-339. Dostupné z DOI: <http://dx.doi.org/10.1006/bbrc.2000.4130>. Go to original source... Go to PubMed...
  12. Kiechl S, Schett G, Wenning G et al. Osteoprotegerin in a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109(18): 2175-2180. Dostupné z DOI: <http://dx.doi.org/10.1161/01.CIR.0000127957.43874.BB>. Go to original source... Go to PubMed...
  13. Introduction: The American Diabetes Association's (ADA) evidence-based practice guidelines, standards, and related recommendations and documents for diabetes care. Diabetes Care 2012; 35(Suppl 1): S1-S2. Dostupné z DOI: <http://dx.doi.org/10.2337/dc12-s001>. Go to original source... Go to PubMed...
  14. Pierdomenico SD, Pierdomenico AM, Cuccurullo F et al. Meta-analysis of the relation of echocardiographic epicardial adipose tissue thickness and the metabolic syndrome. Am J Cardiol 2013; 111(1): 73-78. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2012.08.044>. Go to original source... Go to PubMed...
  15. Xu Y, Cheng X, Hong K et al. How to interpret epicardial adipose tissue as a cause of coronary artery disease: a meta-analysis. Coron Artery Dis 2012; 23(4): 227-233. Dostupné z DOI: <http://dx.doi.org/10.1097/MCA.0b013e328351ab2c>. Go to original source... Go to PubMed...
  16. Wu FZ, Chou JK, Wu MT et al. The relation of location-specific epicardial adipose tissue thickness and obstructive coronary artery disease: systemic review and meta-analysis of observational studies. BMC Cardiovasc Disord 2014; 14: 62. Dostupné z DOI: <http://dx.doi.org/10.1186/1471-2261-14-62>. Go to original source... Go to PubMed...
  17. Prídavková D, Kantárová D, Lišková R et al. Význam epikardiálního tuku a obezitních parametrů při predikcii koronárnej choroby srdca. Vnitř Lék 2016; 62(4): 256-262. Go to PubMed...
  18. Dey D, Nakazato R, Li D et al. Epicardial and thoracic fat-noninvasive measurement and clinical implications. Cardiovasc Diagn Ther 2012; 2(2): 85-93. Dostupné z DOI: <http://dx.doi.org/10.3978/j.issn.2223-3652.2012.04.03>.
  19. Mahabadi AA, Berg MH, Lehmann N et al. Association of epicardial fat with cardiovascular risk factors and incident myocardial infarction in the general population: the Heinz Nixdorf Recall Study. J Am Coll Cardiol 2013; 61(13): 1388-1395. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2012.11.062>. Go to original source... Go to PubMed...
  20. Jeong JW, Jeong MH, Yun KH et al. Echocardiographic epicardial fat thickness and coronary artery disease. Circ J 2007; 71(4): 536-539. Go to original source... Go to PubMed...
  21. Mogelvang R, Pedersen AH, Bjerre M et al. Osteoprotegerin improved risk detection by traditional cardiovascular risk factors and hsCRP. Heart 2013; 99(2): 106-110. Dostupné z DOI: <http://dx.doi.org/10.1136/heartjnl-2012-302240>. Go to original source... Go to PubMed...
  22. Pedersen S, Mogelvang R, Bjerre M et al. Osteoprotegerin predicts long term outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Cardiology 2012; 123(1): 31-38. Dostupné z DOI: <http://dx.doi.org/10.1159/000339880>. Go to original source... Go to PubMed...
  23. Lindberg S, Jensen JS, Hoffmann S et al. Osteoprotegerin levels change during STEMI and reflect cardiac function. Can J Cardiol 2014; 30(12): 1523-1528. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cjca.2014.08.015>. Go to original source... Go to PubMed...
  24. Oguz D, Unal H, Eroglu H et al. Aortic flow propagation velocity, epicardial fat thickness, aned osteoprotegerin level to predict subclinical atherosclerosis in patients with nonalcoholic fatty liver disease. Anatol J Cardiol 2016; 16(12): 974-979. Dostupné z DOI: <http://dx.doi.org/10.14744/AnatolJCardiol.2016.6706>. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.